Repligen Corporation $RGEN Shares Acquired by Aberdeen Group plc

Aberdeen Group plc increased its position in Repligen Corporation (NASDAQ:RGEN) by 17.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,330 shares of the biotechnology company’s stock after purchasing an additional 8,152 shares during the period. Aberdeen Group plc owned 0.10% of Repligen worth $7,262,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after acquiring an additional 400,970 shares in the last quarter. Geneva Capital Management LLC lifted its stake in Repligen by 239.6% during the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares during the last quarter. Blue Whale Capital LLP bought a new position in Repligen during the second quarter worth $35,782,000. Norges Bank acquired a new position in Repligen in the second quarter worth $30,991,000. Finally, Schroder Investment Management Group bought a new stake in Repligen during the second quarter valued at $25,672,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Down 1.1%

RGEN opened at $135.68 on Friday. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The stock has a market cap of $7.64 billion, a P/E ratio of 6,787.39, a P/E/G ratio of 2.50 and a beta of 1.13. The stock’s 50 day moving average price is $156.81 and its 200 day moving average price is $146.10.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RGEN. Wells Fargo & Company raised their price target on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group raised their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. UBS Group upped their target price on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 16th. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. Finally, Barclays boosted their price objective on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.92.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.